Search Results

Viscient Bio, Inc. (“Viscient”) today announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells.

Viscient Biosciences announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medical research institute, and Salk Institute, have published the first demonstration of a liver fibrosis phenotype in a 3D human tissue model of MASH demonstrating strong comparability to the native disease by multiple measures.

Aadi Bioscience expects that pipeline adjustments and the workforce reduction will extend its cash runway into at least the second half of 2026.

Precision BioSciences, Inc. today announced its addition to the Russell Microcap® Index.

Genflow Biosciences Strengthens Pre-Clinical Efforts with FDA Guidance and CDMO and CRO Selection

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), wishes to announce that

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that Company has received a final delisting notice from Nasdaq.

Solid Biosciences Inc. announced that the Company has been added to the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of US equity markets, Monday, July 1st 2024.

Neurocrine Biosciences, Inc. will participate at two upcoming investor conferences in June.